Related references
Note: Only part of the references are listed.Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents
Merav Leiba et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Translational approaches targeting the p53 pathway for anti-cancer therapy
Frank Essmann et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737
Kensuke Kojima et al.
CANCER (2012)
Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
Sylvanie Surget et al.
CANCER RESEARCH (2012)
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils
Alexander H. Stegh
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status
Giorgio Zauli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Therapeutic advancement of chronic lymphocytic leukemia
Kang Lu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
Angela M. Sosin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Richard J. Jones et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
E. McCormack et al.
LEUKEMIA (2012)
Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma
Manujendra N. Saha et al.
PLOS ONE (2012)
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
Richard J. Jones et al.
BLOOD (2011)
NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anti-cancer compounds
Qiao Jing Lew et al.
CELL CYCLE (2011)
Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
Giorgio Zauli et al.
CLINICAL CANCER RESEARCH (2011)
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
Dina Ali et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis
Ahmad Kazemi et al.
HEMATOLOGY (2011)
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
L. F. Peterson et al.
LEUKEMIA (2011)
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
E. Drakos et al.
LEUKEMIA (2011)
A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples
Sona Pekova et al.
LEUKEMIA RESEARCH (2011)
Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia
Amaia Vilas-Zornoza et al.
PLOS ONE (2011)
Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway
Tetsuya Kurosu et al.
APOPTOSIS (2010)
Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
Jianting Long et al.
BLOOD (2010)
Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity
Rebecca Voltan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Nutlin's two roads toward apoptosis
Qi Zhang et al.
CANCER BIOLOGY & THERAPY (2010)
Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma Evidence for p53-transcription-dependent and -independent pathways
Manujendra N. Saha et al.
CANCER BIOLOGY & THERAPY (2010)
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity
Manujendra N. Saha et al.
CANCER BIOLOGY & THERAPY (2010)
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma
Linhua Jin et al.
CANCER LETTERS (2010)
Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim
Weiguo Zhang et al.
CANCER RESEARCH (2010)
Pharmacological activation of the p53 pathway in haematological malignancies
Manujendra N. Saha et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses
Manujendra N. Saha et al.
MOLECULAR CANCER THERAPEUTICS (2010)
1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53
Thelma Thompson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53-and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Kensuke Kojima et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia
P. Secchiero et al.
LEUKEMIA (2010)
Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis
K. Kojima et al.
LEUKEMIA (2010)
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
K. G. Wiman
ONCOGENE (2010)
Therapeutic targeting of p53 by small molecules
Galina Selivanova
SEMINARS IN CANCER BIOLOGY (2010)
The Tumor Suppressor p53: From Structures to Drug Discovery
Andreas C. Joerger et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53
Martin Enge et al.
CANCER CELL (2009)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib
Melissa G. Ooi et al.
CLINICAL CANCER RESEARCH (2009)
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Yoko Tabe et al.
CLINICAL CANCER RESEARCH (2009)
Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity
G. Zauli et al.
CURRENT CANCER DRUG TARGETS (2009)
P53 Family: At the Crossroads in Cancer Therapy
S. Alsafadi et al.
CURRENT MEDICINAL CHEMISTRY (2009)
New targets for the treatment of follicular lymphoma
Nishant Tageja et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Update in the management of chronic lymphocytic leukemia
Kami J. Maddocks et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
Ramzi M. Mohammad et al.
MOLECULAR CANCER (2009)
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53
E. Drakos et al.
LEUKEMIA (2009)
Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells
B. Renouf et al.
LEUKEMIA (2009)
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells
H. Hasegawa et al.
LEUKEMIA (2009)
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma
E. Drakos et al.
LEUKEMIA (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Sanjeev Shangary et al.
Annual Review of Pharmacology and Toxicology (2008)
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism
Andrew J. Steele et al.
BLOOD (2008)
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
Bing Z. Carter et al.
BLOOD (2008)
Mutated and non-mutated TP53 as targets in the treatment of leukaemia
H. Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
p53: A guide to apoptosis
Erik Meulmeester et al.
CURRENT CANCER DRUG TARGETS (2008)
Restoration of p53 to limit tumor growth
Wenge Wang et al.
CURRENT OPINION IN ONCOLOGY (2008)
Inhibition of the Akt/survivin pathway synergizes the antileukernia effect of nutlin-3 in acute lymphoblastic leukemia cells
Ningxi Zhu et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
K. Kojima et al.
LEUKEMIA (2008)
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
L. Gu et al.
LEUKEMIA (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
J. E. Kravchenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
L. M. S. Lau et al.
ONCOGENE (2008)
The MDM-2 antagonist Nutlin-3 promotes the maturation of acute myeloid leukemic blasts
Paola Secchiero et al.
NEOPLASIA (2007)
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma
Elias Drakos et al.
CLINICAL CANCER RESEARCH (2007)
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells
Paola Secchiero et al.
CURRENT DRUG METABOLISM (2007)
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1
G. Ambrosini et al.
ONCOGENE (2007)
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells
Kensuke Kojima et al.
CANCER RESEARCH (2007)
The p53 knowledgebase: an integrated information resource for p53 research
Y. P. Lim et al.
ONCOGENE (2007)
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML
Kensuke Kojima et al.
CELL CYCLE (2006)
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Kensuke Kojima et al.
BLOOD (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
Llorenc Coll-Mulet et al.
BLOOD (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
H Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
T Stühmer et al.
BLOOD (2005)
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
M Krajewski et al.
NATURE MEDICINE (2005)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
VJN Bykov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
p53:: Twenty five years understanding the mechanism of genome protection
M Gomez-Lazaro et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2004)
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
H Nahi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia
X Agirre et al.
MOLECULAR CARCINOGENESIS (2003)
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
VJN Bykov et al.
CARCINOGENESIS (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Regulation and function of the p53 tumor suppressor protein
KM Ryan et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Share Paper
